Company Overview and News

 
Ecopetrol: Fracking Likely In Colombia, Business Prospects Are Positive

2018-09-14 seekingalpha
Ecopetrol SA is a Colombian Oil & Gas Company that has been trading on the NYSE for more than 10 years.
EC

 
EC / Ecopetrol S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-09-11 sec.gov
UNITED STATES SECURITIES AND EXCHAN
EC

 
EC / Ecopetrol S.A. 6-K/A (Current Report of Foreign Issuer)

2018-08-20 sec.gov
UNITED STATES SECURITIES AND EXCHAN
EC

 
Ecopetrol: Strong Q2 Earnings Of Exhausted Producer

2018-08-20 seekingalpha
Ecopetrol S.A. (NYSE:EC) reported solid financial and operating results for 2Q18, where EBITDA and Net Earnings came substantially higher than the market's consensus estimates. EBITDA of COP$8609 million was 10% higher than consensus of COP$7792 million. Net Income was almost 16% higher than Bloomberg consensus.
EC PBR

 
EC / Ecopetrol S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-08-15 sec.gov
UNITED STATES SECURITIES AND EXCHAN
EC

 
EC / Ecopetrol S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-08-09 sec.gov
UNITED STATES SECURITIES AND EXCHAN
EC

 
EC / Ecopetrol S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-08-01 sec.gov
UNITED STATES SECURITIES AND EXCHAN
EC

 
EC / Ecopetrol S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-08-01 sec.gov
UNITED STATES SECURITIES AND EXCHAN
EC

 
Ride Ecopetrol Through the Crude Oil Turbulence

2018-07-30 investorplace
Ecopetrol (NYSE:EC) is the largest oil producer in Colombia. That may not seem like a big deal, but Colombia is the fourth-largest oil producer in Latin America behind Brazil, Mexico and Venezuela.
EC

7
Markets Rise Strongly In Early July, Despite China Fears

2018-07-17 seekingalpha
The S&P 500 is up over 3% in the first half of July and Nasdaq is at an all-time high, despite the ongoing tariff disputes with China. I believe the press has overblown the “trade war” story, but the overall market is waking up to the fact that the likely eventual outcome will be fewer tariffs and fairer trade in the end.
BP EC BBY GPRK WMT SU SU EQNR

1
EC / Ecopetrol S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-07-05 sec.gov - 1
UNITED STATES SECURITIES AND EXCHAN
EC

62
6 Elite Breakout Stocks and How You Can Spot Mega Moves

2018-06-06 investorplace
Editor’s note: Below, you’ll find the second installment of Louis Navellier’s series on how he discovered one of the world’s most powerful short-term trading strategies.
EC HFC EMC NVDA

 
EC / Ecopetrol S.A. F-3ASR

2018-06-01 sec.gov
As filed with the Securities and Exchange Commission on June 1, 2018 Registration No. 333-
EC

2
EC / Ecopetrol S.A. FORM 6-K (Current Report of Foreign Issuer)

2018-05-04 sec.gov - 2
UNITED STATES SECURITIES AND EXCHAN
EC

107
This Week’s Top 10 Stocks Under $20

2018-05-02 investorplace - 1
Here at Zacks, we don’t generally classify stocks as “cheap” or “expensive”, and rather than looking at the stock’s face value, we have a system that puts an emphasis on earnings estimate revisions to find stocks that will hopefully be winners for investors.
AUDC CY LLOBF TRCB ELY EC LLOY CFCO CFCOW LYG CFCOU BBRY LLPH LLPK 2628 LLPJ LLPE LLPD LLPG LLDTF LLD5 CVRR LLD7 LLPC LFC LLD6 LLD1 BB FG LLD2

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

17h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

17h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

19h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to EC / Ecopetrol S.A. on message board site Silicon Investor.

NexOptic Technology Corp NexOptic Technology Corp NexOptic Technology Corp Mainstream Politics and Economics Mainstream Politics and Economics Mainstream Politics and Economics
Items affecting stock market picks Items affecting stock market picks Items affecting stock market picks Buy and Sell Signals, and Other Market Perspectives Buy and Sell Signals, and Other Market Perspectives Buy and Sell Signals, and Other Market Perspectives
Technology Stocks u0026 Market Talk With Don Wolanchuk Technology Stocks u0026 Market Talk With Don Wolanchuk Technology Stocks u0026 Market Talk With Don Wolanchuk Hurricanes: Tracking and Economics Hurricanes: Tracking and Economics Hurricanes: Tracking and Economics
Shiny Objects Shiny Objects Shiny Objects Verde Agritech Verde Agritech Verde Agritech
KULR Technology KULR Technology KULR Technology Severe Weather and the Economic Impact Severe Weather and the Economic Impact Severe Weather and the Economic Impact
CUSIP: 279158109